Scientists / Our Scientists

Rajita Pappu

Director and Principal Scientist, Immunology Discovery

Postdoc Mentor

"The collaborative and science driven environment at Genentech is unparalleled. This enables us to identify and translate novel biological processes into potential therapeutics for the treatment of life-threatening diseases."

Years at Genentech

Publications at Genentech

Awards & Honors

I joined Genentech in 2007 as a scientist in Immunology Discovery after finishing my postdoctoral training at UCSF where I studied the role of Sphingosine-1-phosphate in immunity and vascular development. I was drawn to Genentech because of the high caliber of science and the collaborative environment. These qualities foster creativity and teamwork that is integral to drug discovery.

Postdoctoral Mentor

The postdoctoral program at Genentech provides an excellent opportunity to do cutting-edge research and learn about drug discovery first-hand. The highly collaborative nature of research at Genentech allows postdocs to engage in cross-functional projects, enabling training that encompasses multiple scientific disciplines.

Featured Publication

Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone.

J Allergy Clin Immunol. 2017 Feb;139(2):705-708.e6.

Ramirez-Carrozzi V, Sambandam A, Zhou M, Yan D, Kang J, Wu X, Suto E, Baca M, Austin C, Xu M, Lee W, Pappu R.

View Abstract

My laboratory is interested in understanding the molecular and cellular pathways that promote inflammatory and autoimmune diseases. Within this context we are concentrating on three main areas of research. We are interested in understanding how stromal cell-leukocyte interactions shape immune responses. In particular we have focused on epithelial derived cytokines such as IL-33 and IL-17 family members and their pathogenic properties. Additionally, we are studying how stromal cell -derived signals govern leukocyte migration into inflamed tissues.

We are also investigating what factors regulate ER stress in leukocytes, and how this process contributes to autoimmunity. We use a combination of molecular, cellular, and genetic technologies to interrogate these questions.

Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma

Science Translational Medicine, ISSN: 19466242 19466234

Sarah E. Headland; Hart S. Dengler; Daqi Xu; Grace Teng; Christine Everett; Rojo A. Ratsimandresy; Donghong Yan; Jing Kang; Kirthana Ganeshan; Evgeniya V. Nazarova; Sarah Gierke; Christopher J. Wedeles; Riccardo Guidi; Daryle J. DePianto; Katrina B. Morshead; Alison Huynh; Jessica Mills; Sean Flanagan; Shannon Hambro; Victor Nunez; Joanna E. Klementowicz; Yongchang Shi; Jianyong Wang; Jack Bevers; Vladimir Ramirez-Carrozz; Rajita Pappu; Abbas Alexander; Jason Vander Heiden; David F. Choy; Rajbharan Yadav; Zora Modrusan; Reynold A. Panettieri; Cynthia Koziol-Whit; William F. Jester; Brendan J. Jenkins; Yi Cao; Christine Clarke; Cary D. Austin; Daniel Lafkas; Min Xu; Paul J. Wolters; Joseph R. Arron; Nathaniel West; Mark S. Wilson

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Rajita Pappu

Director and Principal Scientist, Immunology Discovery

Featured Publication

Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone.